English
French
Press Release
|
17 |
Sep 2014 |
IntelGenx to Present at Singular Research 9th Annual Best of the Uncovereds Conference... |
|
21 |
Aug 2014 |
IntelGenx to Present at the Rodman & Renshaw Global Investment Conference... |
|
07 |
Aug 2014 |
IntelGenx Reports Q2, 2014 Results and Provides Corporate Development Update... |
|
18 |
Jul 2014 |
IntelGenx to Host Management Call... |
|
15 |
Jul 2014 |
IntelGenx Announces Management Changes... |
|
01 |
Jul 2014 |
IntelGenx Announces Equity Analyst Coverage by H.C. Wainwright... |
|
21 |
May 2014 |
IntelGenx and RedHill Biopharma Report Positive Bioavailability Study Results in Support of Planned European Marketing A... |
|
13 |
May 2014 |
IntelGenx Reports Q1 2014 Results and Provides Corporate Development Update... |
|
30 |
Apr 2014 |
IntelGenx Announces Government of Canada Funding for CNS VersaFilm(TM) Project... |
|
24 |
Apr 2014 |
IntelGenx and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product... |
|
16 |
Apr 2014 |
IntelGenx Announces Receipt of an Additional U.S. Patent Allowance Related To Proprietary Technology... |
|
11 |
Mar 2014 |
IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update... |
|
03 |
Mar 2014 |
IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines... |
|
26 |
Feb 2014 |
IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology... |
|
24 |
Feb 2014 |
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product... |
|
04 |
Feb 2014 |
IntelGenx and RedHill Biopharma Receive Complete Response Letter from FDA for VersaFilm(TM) Oral Film Product for Acute ... |
|
14 |
Jan 2014 |
IntelGenx Announces Additional Development and Commercialization Agreement with Par Pharmaceutical, Inc. for Two More Pr... |
|
16 |
Dec 2013 |
IntelGenx Closes $3.5 Million Public Offering... |
|
12 |
Dec 2013 |
IntelGenx Announces Public Offering of $3,500,000 of Common Stock... |
|
08 |
Nov 2013 |
IntelGenx Reports Q3, 2013 Results and Corporate Development Highlights... |
|
26 |
Aug 2013 |
IntelGenx Corp. Receives Buprenorphine/Naloxone Sublingual Film Product Patent Infringement Complaint... |
|
22 |
Aug 2013 |
IntelGenx Receives Paragraph IV Certification Letter on Submission of ANDA for Forfivo XL®... |
|
08 |
Aug 2013 |
IntelGenx Reports Q2, 2013 Results and Corporate Development Highlights... |
|
22 |
Jul 2013 |
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Ad... |
|
18 |
Jun 2013 |
IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product... |
|
14 |
May 2013 |
IntelGenx Reports Q1, 2013 Results and Provides Operational Update... |
|
24 |
Apr 2013 |
IntelGenx Secures Leadership Succession... |
|
27 |
Mar 2013 |
IntelGenx submits New Drug Application for Anti-Migraine VersaFilm(TM)... |
|
18 |
Mar 2013 |
IntelGenx to Present at Roth Capital Partners 25th Annual Growth Stock Conference... |
|
18 |
Mar 2013 |
IntelGenx Reports 2012 Annual Results and Provides Operational Update... |
|
11 |
Dec 2012 |
IntelGenx Appoints Rajiv Khosla RPh, PhD, MBA... |
|
13 |
Nov 2012 |
IntelGenx Reports Third Quarter 2012 Results and Highlights Recent Developments... |
|
08 |
Nov 2012 |
IntelGenx Announces Successful Pre-NDA Meeting for Anti-Migraine Film... |
|
09 |
Oct 2012 |
IntelGenx Announces Commercial Launch of Forfivo XL® in USA... |
|
07 |
Aug 2012 |
IntelGenx Reports Second Quarter 2012 Results and Highlights Recent Developments... |
|
14 |
Jun 2012 |
IntelGenx Upgrades to OTCQX(R), the Highest Tier of the OTC Market, on June 14, 2012... |
|
11 |
Jun 2012 |
IntelGenx to present at Bloom Burton & Co. Healthcare Investor Conference... |
|
29 |
May 2012 |
IntelGenx Achieves Positive Pivotal Study Results for Bioequivalent Anti-Migraine VersaFilm™ Formulation of Maxalt-MLT... |
|
15 |
May 2012 |
IntelGenx Reports First Quarter 2012 Results... |
|
24 |
Apr 2012 |
IntelGenx Announces Commencement of Pivotal Clinical Trial for Anti-Migraine VersaFilm™... |
|
29 |
Mar 2012 |
IntelGenx Reports 2011 Annual Results and Provides Operational Update... |
|
15 |
Feb 2012 |
IntelGenx Named to the TSX Venture 50(R) Ranking... |
|
14 |
Feb 2012 |
IntelGenx Announces License Agreement for the Commercialization of CPI-300 in the United States... |
|
05 |
Jan 2012 |
IntelGenx to Present at Biotech Showcase 2012... |
|
26 |
Dec 2011 |
IntelGenx Announces Health Canada Approval for Anti-Migraine VersaFilm™ Pivotal Clinical Trial... |
|
21 |
Dec 2011 |
IntelGenx Announces Development and Commercialization Agreement With Par Pharmaceutical, Inc.... |
|
11 |
Nov 2011 |
IntelGenx Announces FDA Approval of its High Dose Anti-Depressant CPI-300... |
|
09 |
Nov 2011 |
IntelGenx Reports Q3, 2011 Results... |
|
07 |
Nov 2011 |
FDA Revises IntelGenx' CPI-300 PDUFA Date to November 10th... |
|
06 |
Sep 2011 |
IntelGenx to Present at the Rodman & Renshaw 13th Annual Healthcare Conference in New York... |
|
09 |
Aug 2011 |
IntelGenx Reports Q2, 2011 Results and Highlights Recent Developments... |
|
02 |
Aug 2011 |
IntelGenx Announces Successful Pre-Approval Inspection of its Lead Product CPI-300... |
|
22 |
Jun 2011 |
IntelGenx Announces Closing of Private Placements... |
|
14 |
Jun 2011 |
IntelGenx Announces New PDUFA Date for Its Single Dose 450 mg Bupropion Hydrochloride Tablet... |
|
03 |
Jun 2011 |
IntelGenx Announces Up to Approximately US$3 Million Equity Offering of Common Stock and Warrants... |
|
24 |
May 2011 |
IntelGenx Welcomes Dr. Rajiv Khosla to Its Board... |
|
16 |
May 2011 |
IntelGenx Submits Reply to FDA Complete Response Letter for its Single Dose 450 mg Bupropion Hydrochloride Tablet... |
|
11 |
May 2011 |
IntelGenx Reports Q1, 2011 Results and Highlights Recent Developments... |
|
07 |
Apr 2011 |
IntelGenx Completes Positive Bioequivalence Study with Insomnia Thin Film... |
|
30 |
Mar 2011 |
IntelGenx Reports 2010 Financial Results and Summarizes Key Developments... |
|
04 |
Mar 2011 |
IntelGenx Announces Departure of Director... |
|
07 |
Feb 2011 |
IntelGenx Achieves Positive Bioequivalence Results for a Leading Branded Anti-Psychotic Using VersaFilm™ Oral Thin Fil... |
|
03 |
Feb 2011 |
IntelGenx Announces Dismissal of Patent Litigation Relating to Its Once Daily High Dose 450 mg Bupropion Hydrochloride T... |
|
11 |
Jan 2011 |
Webcast: Horst G. Zerbe Presents at OneMedForum... |
|
05 |
Jan 2011 |
IntelGenx to Present at OneMedForum Conference in San Francisco... |
|
04 |
Jan 2011 |
IntelGenx Receives Positive Ruling in Patent Litigation Hearing... |
|
29 |
Nov 2010 |
IntelGenx Acquires Full Ownership and Exclusive Rights to MS Induced Pain Product... |
|
10 |
Nov 2010 |
IntelGenx Reports Third Quarter 2010 Results and Highlights Recent Developments... |
|
02 |
Sep 2010 |
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction Film Product... |
|
30 |
Aug 2010 |
IntelGenx and RedHill Announce Definitive Agreement for Anti-Migraine Film Product... |
|
27 |
Aug 2010 |
IntelGenx Announces Closing of Private Placement... |
|
12 |
Aug 2010 |
IntelGenx Reports Second Quarter 2010 Results and Highlights Recent Developments... |
|
11 |
Aug 2010 |
IntelGenx Announces Additions to Board and Issuance of Stock Options... |
|
21 |
Jun 2010 |
IntelGenx Reports on Meeting With FDA... |
|
14 |
May 2010 |
IntelGenx Announces the Adjournment of the 2010 Annual General Meeting of Shareholders... |
|
14 |
May 2010 |
IntelGenx Announces the Adjournment of the 2010 Annual General Meeting of ShareholdersIntelGenx Reports First Quarter 20... |
|
11 |
May 2010 |
IntelGenx Acquires Full Ownership of High Dose Bupropion (CPI-300)... |
|
04 |
May 2010 |
IntelGenx Announces Manufacturing Partnership and Ownership Position in Manufacturing Facility... |
|
21 |
Apr 2010 |
IntelGenx Announces Licensing of Anti-Migraine Film Product... |
|
07 |
Apr 2010 |
IntelGenx to Present at BioFinance 2010... |
|
31 |
Mar 2010 |
IntelGenx Reports Q4 and Full Year 2009 Financial Results and Summarizes Development Milestones Achieved... |
|
10 |
Mar 2010 |
IntelGenx Granted Bupropion Patent... |
|
04 |
Mar 2010 |
IntelGenx and Cannasat Announce Letter of Intent for Relivar License... |
|
08 |
Feb 2010 |
IntelGenx Receives FDA Complete Response Letter CPI-300... |
|
25 |
Jan 2010 |
IntelGenx Enters Strategic Manufacturing Partnership for VersaFilm™ Technology... |
|
22 |
Jan 2010 |
IntelGenx Grants Options to IR Firm... |
|
21 |
Jan 2010 |
IntelGenx Receives Notice of Allowance for Bupropion Patent... |
|
11 |
Jan 2010 |
IntelGenx Announces Manufacturing Site Change for CPI-300... |
|
17 |
Nov 2009 |
IntelGenx Achieves Positive Bioequivalence Results With Novel Anti-Migraine Film... |
|
10 |
Nov 2009 |
IntelGenx Reports Results For the Third Quarter and Nine Months Ended September 30, 2009... |
|
06 |
Oct 2009 |
IntelGenx Determines Exercise Price of Stock Options to IR Firm... |
|
01 |
Oct 2009 |
IntelGenx Strengthens Investor Relations Activities... |
|
04 |
Sep 2009 |
IntelGenx Technologies Corp. Completes Additional Private Placement... |
|
31 |
Aug 2009 |
IntelGenx Technologies Corp. Announces Shareholder Call... |
|
21 |
Aug 2009 |
IntelGenx Corp. Comments on CPI-300 Patent Infringement Complaint... |
|
14 |
Aug 2009 |
IntelGenx Reports Results for the Second Quarter and Six Months Ended June 30, 2009... |
|
29 |
Jul 2009 |
IntelGenx Technologies Corp. Files Preliminary Short Form Prospectus; IntelGenx Completes Additional Private Placement... |
|
14 |
Jul 2009 |
IntelGenx Technologies Corp. Announces Closing of Private Placement... |
|
23 |
Jun 2009 |
IntelGenx Corp. Announces FDA Acceptance for Filing of NDA for CPI-300 Antidepressant... |
|
19 |
May 2009 |
IntelGenx Corp. and Circ Pharma to Commence Phase 1 Proof-of-Concept Study of CRES Pravastatin, a Novel Low Dose Formula... |